FY2025 Earnings Estimate for Clorox Issued By Zacks Research

The Clorox Company (NYSE:CLX - Free Report) - Analysts at Zacks Research dropped their FY2025 earnings per share (EPS) estimates for Clorox in a report issued on Monday, May 19th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $7.09 per share for the year, down from their previous forecast of $7.15. The consensus estimate for Clorox's current full-year earnings is $7.15 per share. Zacks Research also issued estimates for Clorox's Q4 2026 earnings at $2.11 EPS and FY2027 earnings at $7.34 EPS.

Other equities analysts also recently issued reports about the company. Evercore ISI set a $140.00 target price on Clorox and gave the company an "underperform" rating in a research note on Tuesday, May 6th. Royal Bank of Canada restated a "sector perform" rating and issued a $150.00 target price on shares of Clorox in a research note on Thursday, January 30th. DA Davidson decreased their target price on Clorox from $171.00 to $169.00 and set a "neutral" rating for the company in a research note on Wednesday, February 5th. Wells Fargo & Company decreased their target price on Clorox from $145.00 to $142.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Finally, Citigroup decreased their price objective on Clorox from $165.00 to $150.00 and set a "neutral" rating for the company in a report on Monday, April 14th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Clorox presently has a consensus rating of "Hold" and an average target price of $151.23.

Clorox Stock Performance

CLX stock traded down $0.03 during midday trading on Thursday, reaching $130.85. The company had a trading volume of 642,391 shares, compared to its average volume of 1,331,413. The company has a quick ratio of 0.60, a current ratio of 0.94 and a debt-to-equity ratio of 20.52. The stock has a 50 day moving average price of $139.35 and a 200 day moving average price of $152.00. Clorox has a fifty-two week low of $127.60 and a fifty-two week high of $171.37. The firm has a market capitalization of $16.13 billion, a PE ratio of 35.73, a P/E/G ratio of 2.62 and a beta of 0.60.

Clorox (NYSE:CLX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.12). The firm had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.74 billion. Clorox had a net margin of 6.38% and a return on equity of 316.87%. The firm's quarterly revenue was down 8.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.71 earnings per share.

Insider Buying and Selling at Clorox

In other news, Director Pierre R. Breber purchased 4,000 shares of the firm's stock in a transaction on Wednesday, May 7th. The stock was purchased at an average cost of $136.57 per share, with a total value of $546,280.00. Following the purchase, the director now owns 4,000 shares in the company, valued at $546,280. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.57% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Clorox

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of Clorox during the 4th quarter valued at $259,041,000. Hsbc Holdings PLC lifted its position in shares of Clorox by 118.8% during the 1st quarter. Hsbc Holdings PLC now owns 1,085,661 shares of the company's stock valued at $159,699,000 after acquiring an additional 589,544 shares during the last quarter. FMR LLC lifted its position in shares of Clorox by 75.4% during the 4th quarter. FMR LLC now owns 1,361,758 shares of the company's stock valued at $221,163,000 after acquiring an additional 585,526 shares during the last quarter. KBC Group NV lifted its position in shares of Clorox by 688.7% during the 1st quarter. KBC Group NV now owns 587,679 shares of the company's stock valued at $86,535,000 after acquiring an additional 513,171 shares during the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Clorox by 412.1% during the 1st quarter. AQR Capital Management LLC now owns 598,758 shares of the company's stock valued at $88,167,000 after acquiring an additional 481,846 shares during the last quarter. 78.53% of the stock is owned by institutional investors.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.